Catabasis Pharmaceuticals (NASDAQ:CATB) issued its earnings results on Thursday. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.08, MarketWatch Earnings reports.
Catabasis Pharmaceuticals stock traded up $0.32 during trading on Friday, hitting $6.12. 4,081 shares of the company were exchanged, compared to its average volume of 192,286. Catabasis Pharmaceuticals has a 52 week low of $3.60 and a 52 week high of $21.80. The company has a market capitalization of $41.78 million, a P/E ratio of -0.48 and a beta of 1.64.
A number of brokerages have recently weighed in on CATB. Zacks Investment Research lowered Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 14th. ValuEngine downgraded Catabasis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 4th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $31.38.
ILLEGAL ACTIVITY NOTICE: This story was first published by Week Herald and is owned by of Week Herald. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://weekherald.com/2019/03/15/catabasis-pharmaceuticals-catb-releases-earnings-results-beats-estimates-by-0-08-eps.html.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases.
Read More: Why is the price-sales ratio important?
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.